Antonio Postigo

Antonio Postigo

Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer

Life & Medical Sciences

CURRENT POSITIONS:  * ICREA Professor of Life & Medical Sciences. IDIBAPS Research Institute (Barcelona) * Adjunct Visiting Professor, JG Brown Cancer Center, Univ. Louisville School of Medicine (USA) * Adjunct Lecturer, Dept. of Biomedicine. Univ. of Barcelona School of Medicine (Barcelona) RESEARCH FUNDING:  * Public Agencies: European Commission / National Research Agency - Spanish Ministry of Science & Innovation / Catalan Agency for University & Research Grants (AGAUR) * Private Foundations: Leukemia Research Foundation / Duchenne Parent Project / AVON Breast Cancer Campaign / Spanish Association Against Cancer (AECC) / La Marató TV3 Foundation / Olga Torres Foundation / La Caixa Foundation / Catalan Academy of Medical & Health Sciences. OTHER WEBSITES & SOCIAL MEDIA HANDLES: IDIBAPS:  Twitter: @GeneRegLab

Research interests

Our group studies the molecular mechanisms that regulate cell plasticity in health and disease with a particular focus on transcriptional regulation. Ongoing projects investigate gene regulation in inflammation, cancer initiation and progression, stem cell determination and differentiation, and tissue injury and regeneration. We use a wide range of technical approaches that include unique conditional transgenic mice, ex vivo culture and manipulation of normal and malignant primary cells, differentiation of human embryonic stem cells, and high-throughput techniques (e.g., RNAseq, scRNAseq, proteomics). As molecular models, we use the EMT transcription factors ZEB1 and ZEB2 which play key roles in the regulation of cell plasticity.

Selected publications

- Pedrosa L, C Foguet, H Oliveres, I Archilla, M Garcıa de Herreros, A Rodrıguez, A Postigo, D Benıtez-Ribas, J Camps, M Cuatrecasas, A Castells, A Prat, TM Thomson, JM Maurel, M Cascante 2022, 'A novel gene signature unveils three distinct immune-metabolic rewiring patterns conserved across diverse tumor types and associated with outcomes'. Front. Immunol. 13:926304. IF: 8.8    

- Lahoz A, A Rodríguez, L Fernández, T Gorría, R Moreno, F Esposito, H Oliveres, S Albiol, T Saurí, D Pesantez, G Riu, M Cuatrecasas, P Jares, L Pedrosa, E Pineda, A Potigo, A Castells, A Prat, J Maurel , J Camps 2022 'Mutational status of SMAD4 and FBXW7 affects clinical outcome in TP53-mutated metastatic colorectal cancer'. Cancers. 14(23):5921. IF 6.6

- Guo Y, Lu X, Chen Y, Clark G, Trent J, Cuatrecasas M, Emery D, Song ZH, Chariker J, Rouchka E, Postigo A*, Liu Y* & Dean DC* 2022, 'Opposing roles of ZEB1 in the cytoplasm and nucleus control cytoskeletal assembly and YAP1 activity. Cell Reports, 41(1):111452. IF: 9.9.